கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் நிதி மீடியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1 : Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts. SNG001 is a formulation containing IFN-beta for nebulisation, allowing it to be delivered directly into patients’ lungs. A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells. Furthermore, some people have deficiencies in antiviral IFN signalling that make them more vulnerable to spread of the virus from the nose into the lungs where it can cause severe breathing difficulties. These findings provide a rationale to deliver IFN-beta directly to the surface epithelial cells of the lungs, the primary site of virus infection in the lungs, to pr

United kingdomOlivia manserGeoff nashMary conwayNick francisRichard marsdenJohn wardTom wilkinsonDonna daviesDuncan monteithJessica hodgsonJames blackKate bannatyneRatko djukanovicMary jane elliottFreddie barnfield